Abstracts

Bacterial Vaginosis

Background: This session focuses on current evidence for the role of bacterial vaginosis (BV) in HIV acquisition and transmission and based on this how future research on the vaginal microbiome may help to inform HIV prevention interventions. Our understanding of normal and abnormal vaginal flora including BV has undergone radical shifts during the past decade.…

Lymphogranuloma venereum

Background: Lymphogranuloma venereum (LGV), caused by lymphotropic invasive strains of Chlamydia trachomatis (L1-L3 serovars), is a sexually transmitted infection characterised by severe inflammation, often with systemic symptoms. The clinical course of LGV can be divided into three stages. The primary stage, often unnoticed by the patient, consists of a small painless papule which may ulcerate.…

Genotypic Tropism Testing of Proviral DNA to Guide Maraviroc Initiation in Aviremic Subjects

Background: Maraviroc (MVC) is a suitable drug for aviremic subjects on antiretroviral treatment (ART) developing toxicity, but its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable to guide MVC initiation in aviremic subjects. Methodology: This was a Phase 4, prospective, single-arm study (ID: NCT01378910) in 24 HIV…

Feasibility and Clinical Utility of HIV-1 Genotype Testing in the Setting of Low-level Viremia

Background: We evaluated reliability and clinical usefulness of genotypic resistance testing (GRT), in patients failing combination antiretroviral therapy (cART) with viremia levels 50-1000 copies/mL, for whom GRT is generally not recommended by current guidelines. Methodology: Genotyping success rate (GSR) was evaluated in 12828 HIV-1 plasma samples with viremia >50 copies/mL, tested using the commercial ViroSeq…

Celera RUO Integrase Resistance Assay Performs Well Across Several Subtypes

Background: Sequence variation is a major obstacle to developing molecular based assays for multiple subtypes. This study sought to independently assess performance characteristics of the ViroSeq™ HIV-1 Integrase RUO Genotyping Kit (Celera, US) for samples of multiple different subtypes. Methodology: 157 samples were used in the validation, 105 from integrase inhibitor naive patients’ plasma samples…

Characterization of NNRTI Mutations in HIV-1 RT*Using Single Molecule Real-Time SMRT®*Sequencing

Background: Genotypic testing of chronic viral infections is an important part of patient therapy and requires assays capable of detecting the entire spectrum of viral mutations. Single Molecule, Real-Time (SMRT) sequencing offers several advantages to other sequencing technologies, including superior resolution of mixed populations and long read lengths capable of spanning entire viral protein coding…

Long-Term Benefit Of Tenofovir On Hepatitis Delta

Background: Hepatitis delta virus (HDV) infection produces the most severe form of chronic viral hepatitis. Treatment with peginterferon gives only limited benefit on delta hepatitis. Since HDV replication requires HBsAg and tenofovir is amongst the most potent anti-HBV agents and is widely used as part of HIV therapy, we explored whether prolonged tenofovir (TDF) exposure…